Alembic Pharmaceuticals (Alembic) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Binimetinib Tablets, 15 mg and 45 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Mektovi Tablets, 15 mg, of Array BioPharma Inc. (Array). Binimetinib is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. It is also indicated, in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.
Alembic was one of the first ANDA applicants for 15 mg and sole first applicant for 45 mg to submit substantially complete ANDA with a paragraph IV certification for Binimetinib Tablets. Therefore, with this approval, Alembic is eligible for 180 days of generic drug exclusivity for Binimetinib Tablets, 15 mg and 45 mg.
Binimetinib tablets have an estimated market size of $282 million for twelve months ending September 2026 according to IQVIA. Alembic has a cumulative total of 248 ANDA approvals (230 final approvals and 18 tentative approvals) from the USFDA.
Alembic Pharmaceuticals is involved in manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities.